BR0317103A - Dispersões sólidas comprendendo um fármaco higroscópico e/ou deliquescente - Google Patents
Dispersões sólidas comprendendo um fármaco higroscópico e/ou deliquescenteInfo
- Publication number
- BR0317103A BR0317103A BR0317103-5A BR0317103A BR0317103A BR 0317103 A BR0317103 A BR 0317103A BR 0317103 A BR0317103 A BR 0317103A BR 0317103 A BR0317103 A BR 0317103A
- Authority
- BR
- Brazil
- Prior art keywords
- hygroscopic
- hydroxy
- drug
- cellulose
- carrier medium
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Addiction (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
Abstract
"DISPERSõES SóLIDAS COMPREENDENDO UM FáRMACO HIGROSCóPICO E/OU DELIQuESCENTE". Fornece-se uma composição farmacêutica que compreende uma dispersão sólida que tem um meio veicular que compreende (a) um agente formador de matriz selecionado entre hidróxi-etil-celulose, hidróxi-propil-celulose, hidróxipropil-metil-celulose, ftalato de hidróxi-propil-metil-celulose, poli(vinil-pirrolidona), polietilenoglicol, glicerídeos poliglicolizados, ciclodextrinas e carbómeros, e (b) uma carga, e tendo um fármaco higroscópico e/ou deliq³escente dispersado ou dissolvido no meio veicular. A composição é, de forma aceitável, não higroscópica.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43542202P | 2002-12-19 | 2002-12-19 | |
US43514702P | 2002-12-19 | 2002-12-19 | |
US43502202P | 2002-12-19 | 2002-12-19 | |
PCT/US2003/039510 WO2004060353A1 (en) | 2002-12-19 | 2003-12-11 | Solid dispersions comprising a hygroscopic and/or deliquescent drug |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0317103A true BR0317103A (pt) | 2005-10-25 |
Family
ID=32719157
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0317392-5A BR0317392A (pt) | 2002-12-19 | 2003-12-05 | Formulação não-higroscópica incluindo uma droga higroscópica |
BR0317103-5A BR0317103A (pt) | 2002-12-19 | 2003-12-11 | Dispersões sólidas comprendendo um fármaco higroscópico e/ou deliquescente |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0317392-5A BR0317392A (pt) | 2002-12-19 | 2003-12-05 | Formulação não-higroscópica incluindo uma droga higroscópica |
Country Status (17)
Country | Link |
---|---|
US (2) | US20040197411A1 (pt) |
EP (2) | EP1575563B1 (pt) |
JP (2) | JP2006513238A (pt) |
AR (2) | AR042511A1 (pt) |
AT (1) | ATE353633T1 (pt) |
AU (2) | AU2003298010A1 (pt) |
BR (2) | BR0317392A (pt) |
CA (2) | CA2511385A1 (pt) |
DE (1) | DE60311875T2 (pt) |
ES (1) | ES2280835T3 (pt) |
HN (1) | HN2003000417A (pt) |
MX (2) | MXPA05006802A (pt) |
NL (1) | NL1025069C2 (pt) |
PE (1) | PE20040972A1 (pt) |
TW (2) | TW200423971A (pt) |
UY (1) | UY28138A1 (pt) |
WO (2) | WO2004060352A1 (pt) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1243262T3 (da) | 2001-03-20 | 2006-10-02 | Sanol Arznei Schwarz Gmbh | Hidtil ukendt anvendelse af en peptidklasse af forbindelser til behandling af ikke-neuropatiske, inflammatoriske smerter |
EP1243263B1 (en) * | 2001-03-21 | 2002-11-27 | Schwarz Pharma Ag | Novel use of a peptide class of compound for treating allodynia or other different types of chronic or phantom pain |
SE521512C2 (sv) * | 2001-06-25 | 2003-11-11 | Niconovum Ab | Anordning för administrering av en substans till främre delen av en individs munhåla |
ES2280835T3 (es) * | 2002-12-19 | 2007-09-16 | Pharmacia Corporation | Formulacion no higroscopica que comprende un farmaco higroscopico. |
KR20050096922A (ko) | 2002-12-20 | 2005-10-06 | 니코노범 에이비 | 물리적 및 화학적으로 안정된 니코틴 함유 입자물질 |
US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
US8377952B2 (en) | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
FR2865133B1 (fr) * | 2004-01-19 | 2008-01-18 | Rytek | Compositions pour le traitement de pathologies digestives |
US8980894B2 (en) | 2004-03-25 | 2015-03-17 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure |
EP1579862A1 (en) | 2004-03-25 | 2005-09-28 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure |
KR20070007931A (ko) | 2004-04-16 | 2007-01-16 | 쉬바르츠파르마에이지 | 만성 두통의 예방 및 치료를 위한 펩티드 화합물의 용도 |
EP1765309B1 (en) * | 2004-07-02 | 2009-08-05 | Radi Medical Biodegradable AB | Smokeless toabacco product |
EA014055B1 (ru) | 2004-08-27 | 2010-08-30 | Шварц Фарма Аг | Применение пептидных соединений для лечения боли при раке кости, а также боли, вызванной химиотерапией и нуклеозидами |
US20060147518A1 (en) * | 2004-12-30 | 2006-07-06 | Pierre Fabre Medicament | Stable solid dispersion of a derivative of vinca alkaloid and process for manufacturing it |
US20070048372A1 (en) * | 2005-08-18 | 2007-03-01 | Srz Properties, Inc. | Method for treating non-inflammatory osteoarthritic pain |
EP1754476A1 (en) * | 2005-08-18 | 2007-02-21 | Schwarz Pharma Ag | Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia |
US20070043120A1 (en) * | 2005-08-18 | 2007-02-22 | Bettina Beyreuther | Therapeutic combination for painful medical conditions |
US20090304786A1 (en) * | 2005-11-25 | 2009-12-10 | Viswaprasad Varanasi | Stable Dosage Forms of an Antidepressant |
AU2007224584A1 (en) | 2006-03-16 | 2007-09-20 | Niconovum Ab | Improved snuff composition |
RU2406502C2 (ru) * | 2006-06-06 | 2010-12-20 | Тиботек Фармасьютикалз Лтд. | Способ получения препаратов тмс125, полученных сушкой распылением |
TWI397417B (zh) | 2006-06-15 | 2013-06-01 | Ucb Pharma Gmbh | 具有協同抗驚厥功效之醫藥組成物 |
EP1920785A1 (en) | 2006-11-07 | 2008-05-14 | Boehringer Ingelheim Vetmedica Gmbh | Liquid preparation comprising a complex of pimobendan and cyclodextrin |
CA2673536A1 (en) * | 2006-12-22 | 2008-07-03 | Yuhan Corporation | Revaprazan-containing solid dispersion and process for the preparation thereof |
US9358242B2 (en) * | 2007-08-30 | 2016-06-07 | Prelief Inc. | Calcium glycerophosphate for treating and preventing respiratory diseases or conditions |
WO2009029705A1 (en) * | 2007-08-30 | 2009-03-05 | Prelief Inc. | Calcium glycerophosphate for treating and preventing respiratory diseases or conditions |
KR101499533B1 (ko) * | 2008-02-15 | 2015-03-09 | 주식회사 씨티씨바이오 | 콜린 알포세레이트 함유 약학 제제 |
DE102008020701A1 (de) * | 2008-04-24 | 2009-10-29 | Bayer Technology Services Gmbh | Formulierung mit reduzierter Hygroskopizität |
DE102008047910A1 (de) | 2008-09-19 | 2010-03-25 | Molkerei Meggle Wasserburg Gmbh & Co. Kg | Tablettierhilfsstoff auf Laktose- und Cellulosebasis |
KR101172699B1 (ko) | 2011-05-16 | 2012-08-09 | 한국프라임제약주식회사 | 콜린알포세레이트를 함유하는 약학 제제, 및 그의 제조방법 |
JP2014522893A (ja) | 2011-07-07 | 2014-09-08 | ザ ルブリゾル コーポレイション | 2ストロークサイクルエンジンのための改善された清浄性を提供する潤滑剤 |
CN102525992A (zh) * | 2012-03-09 | 2012-07-04 | 徐奎 | L-α-甘油磷酸胆碱薄膜衣片及其制备方法 |
ES2924478T3 (es) | 2012-03-15 | 2022-10-07 | Boehringer Ingelheim Vetmedica Gmbh | Formulación de comprimidos farmacéuticos para el sector médico veterinario, método de producción y uso de los mismos |
WO2013175505A1 (en) * | 2012-05-21 | 2013-11-28 | Hetero Research Foundation | Elvitegravir solid dispersion |
CN113181110A (zh) | 2013-07-19 | 2021-07-30 | 勃林格殷格翰动物保健有限公司 | 含有防腐的醚化的环糊精衍生物的液体水性药物组合物 |
WO2015082389A1 (en) | 2013-12-04 | 2015-06-11 | Boehringer Ingelheim Vetmedica Gmbh | Improved pharmaceutical compositions of pimobendan |
GB2525170A (en) * | 2014-04-07 | 2015-10-21 | Nokia Technologies Oy | Stereo viewing |
CN104739776A (zh) * | 2015-04-15 | 2015-07-01 | 福州乾正药业有限公司 | 左卡尼汀的固体分散体组合物及其制备方法和药物应用 |
WO2017013591A1 (en) * | 2015-07-22 | 2017-01-26 | Leiutis Pharmaceuticals Pvt Ltd | Stabilized liquid formulation of levothyroxine |
BR112018068986B1 (pt) * | 2016-03-18 | 2023-03-21 | Christopher Brian Reid | Composição para reduzir a expressão oncógena de uma célula, tecido ou órgão de um indivíduo |
US10537570B2 (en) | 2016-04-06 | 2020-01-21 | Boehringer Ingelheim Vetmedica Gmbh | Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease |
JP7319247B2 (ja) * | 2018-03-30 | 2023-08-01 | 株式会社カネカ | 酸化型グルタチオンを含む固体組成物及びその製造方法 |
CN112316678A (zh) * | 2020-10-12 | 2021-02-05 | 常州市永勃机械有限公司 | 一种变电站柜体用驱潮剂制备工艺制备方法 |
IT202100018578A1 (it) * | 2021-07-14 | 2023-01-14 | Indena Spa | Dispersione amorfa di maltolo ferrico e relativo processo di preparazione |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4835187A (en) * | 1987-06-15 | 1989-05-30 | American Home Products Corporation | Spray dried ibuprofen |
JPH02218621A (ja) * | 1989-02-20 | 1990-08-31 | Nippon Chemiphar Co Ltd | 徐放性製剤 |
US5582837A (en) * | 1992-03-25 | 1996-12-10 | Depomed, Inc. | Alkyl-substituted cellulose-based sustained-release oral drug dosage forms |
SE9303574D0 (sv) * | 1993-11-01 | 1993-11-01 | Kabi Pharmacia Ab | Composition for drug delivery and method the manufacturing thereof |
EP0729748B1 (en) * | 1993-11-18 | 2003-02-26 | Nippon Shinyaku Company, Limited | Process for producing stable medicinal composition |
JPH08157392A (ja) * | 1994-12-01 | 1996-06-18 | Kanegafuchi Chem Ind Co Ltd | 放出制御型製剤 |
GB9607955D0 (en) * | 1996-04-17 | 1996-06-19 | Tillotts Pharma Ag | Hydrophobic carbomer salt compositions |
JPH10182448A (ja) * | 1996-12-24 | 1998-07-07 | Zensei Yakuhin Kogyo Kk | 圧縮製剤用組成物の製造方法 |
MA25590A1 (fr) * | 1998-09-14 | 2002-12-31 | Inhale Therapeutic Syst | Agent actif de delivraison de poudre seche |
US6264981B1 (en) * | 1999-10-27 | 2001-07-24 | Anesta Corporation | Oral transmucosal drug dosage using solid solution |
MY135721A (en) * | 2000-03-24 | 2008-06-30 | Pharmacia Corp | Amidino compounds useful as nitric oxide synthase inhibitors |
US20020143058A1 (en) * | 2001-01-24 | 2002-10-03 | Taro Pharmaceutical Inductries Ltd. | Process for preparing non-hygroscopic sodium valproate composition |
ES2280835T3 (es) * | 2002-12-19 | 2007-09-16 | Pharmacia Corporation | Formulacion no higroscopica que comprende un farmaco higroscopico. |
-
2003
- 2003-12-05 ES ES03796731T patent/ES2280835T3/es not_active Expired - Lifetime
- 2003-12-05 EP EP03796731A patent/EP1575563B1/en not_active Expired - Lifetime
- 2003-12-05 CA CA002511385A patent/CA2511385A1/en not_active Abandoned
- 2003-12-05 WO PCT/US2003/038792 patent/WO2004060352A1/en active IP Right Grant
- 2003-12-05 MX MXPA05006802A patent/MXPA05006802A/es unknown
- 2003-12-05 AT AT03796731T patent/ATE353633T1/de not_active IP Right Cessation
- 2003-12-05 DE DE60311875T patent/DE60311875T2/de not_active Expired - Fee Related
- 2003-12-05 JP JP2004565235A patent/JP2006513238A/ja active Pending
- 2003-12-05 BR BR0317392-5A patent/BR0317392A/pt not_active IP Right Cessation
- 2003-12-05 AU AU2003298010A patent/AU2003298010A1/en not_active Abandoned
- 2003-12-11 AU AU2003296948A patent/AU2003296948A1/en not_active Abandoned
- 2003-12-11 CA CA002509261A patent/CA2509261A1/en not_active Abandoned
- 2003-12-11 JP JP2004565403A patent/JP2006514052A/ja not_active Withdrawn
- 2003-12-11 EP EP03814729A patent/EP1575564A1/en not_active Withdrawn
- 2003-12-11 MX MXPA05005667A patent/MXPA05005667A/es unknown
- 2003-12-11 WO PCT/US2003/039510 patent/WO2004060353A1/en not_active Application Discontinuation
- 2003-12-11 BR BR0317103-5A patent/BR0317103A/pt not_active IP Right Cessation
- 2003-12-17 TW TW092135756A patent/TW200423971A/zh unknown
- 2003-12-17 AR ARP030104684A patent/AR042511A1/es unknown
- 2003-12-18 NL NL1025069A patent/NL1025069C2/nl not_active IP Right Cessation
- 2003-12-18 US US10/741,530 patent/US20040197411A1/en not_active Abandoned
- 2003-12-18 AR ARP030104716A patent/AR042536A1/es unknown
- 2003-12-18 US US10/741,526 patent/US20050013856A1/en not_active Abandoned
- 2003-12-18 TW TW092135960A patent/TW200413006A/zh unknown
- 2003-12-19 UY UY28138A patent/UY28138A1/es not_active Application Discontinuation
- 2003-12-19 HN HN2003000417A patent/HN2003000417A/es unknown
-
2004
- 2004-01-05 PE PE2004000027A patent/PE20040972A1/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2509261A1 (en) | 2004-07-22 |
EP1575563B1 (en) | 2007-02-14 |
BR0317392A (pt) | 2005-12-20 |
WO2004060352A1 (en) | 2004-07-22 |
JP2006514052A (ja) | 2006-04-27 |
ES2280835T3 (es) | 2007-09-16 |
DE60311875T2 (de) | 2007-08-30 |
US20050013856A1 (en) | 2005-01-20 |
MXPA05005667A (es) | 2005-07-26 |
NL1025069C2 (nl) | 2005-02-16 |
HN2003000417A (es) | 2005-11-01 |
EP1575564A1 (en) | 2005-09-21 |
NL1025069A1 (nl) | 2004-07-01 |
UY28138A1 (es) | 2004-08-31 |
CA2511385A1 (en) | 2004-07-22 |
ATE353633T1 (de) | 2007-03-15 |
PE20040972A1 (es) | 2004-12-14 |
TW200423971A (en) | 2004-11-16 |
AU2003298010A1 (en) | 2004-07-29 |
JP2006513238A (ja) | 2006-04-20 |
AR042536A1 (es) | 2005-06-22 |
WO2004060353A1 (en) | 2004-07-22 |
US20040197411A1 (en) | 2004-10-07 |
TW200413006A (en) | 2004-08-01 |
WO2004060353A9 (en) | 2004-10-07 |
EP1575563A1 (en) | 2005-09-21 |
DE60311875D1 (de) | 2007-03-29 |
AR042511A1 (es) | 2005-06-22 |
MXPA05006802A (es) | 2005-09-08 |
WO2004060352A8 (en) | 2005-09-15 |
AU2003296948A1 (en) | 2004-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0317103A (pt) | Dispersões sólidas comprendendo um fármaco higroscópico e/ou deliquescente | |
PT1183014E (pt) | Composicoes farmaceuticas orais de libertacao controlada e de dissimulacao de sabor | |
GT200600474A (es) | Composiciones farmaceuticas solidas que contienen pregabalina | |
MY136318A (en) | Sustained-release tablet composition | |
BRPI0408396A (pt) | pelìculas de dissolução rápida, consumìveis por via oral, contendo agentes farmaceuticamente ativos | |
ATE279392T1 (de) | Indol-verbindungen, verfahren zu ihrer herstellung, sie enthaltende pharmazeutische zusammensetzungen und ihre medizinische anwendung | |
IL131651A0 (en) | A pharmaceutical formulation containing benzimidazoles with amino acid/caclodextrin combinations and a process for producing the same | |
ATE383165T1 (de) | Pharmazeutische zusammensetzung mit verzögerter freisetzung, die wasserunlösliche komplexverbindungen enthalten | |
DE59707812D1 (de) | Opioidantagonisthaltige galenische formulierung | |
FI955215A0 (fi) | Hallitusti vapauttavat oksibutyniinivalmisteet | |
NO20014035L (no) | System for oral administrasjon av medikament | |
MXPA97002401A (es) | Agente antiinflamatorio para uso externo. | |
HK1045113A1 (zh) | 給予固定的曲馬朵和雙氯酚酸組合的口服給藥形式 | |
DE69715009T2 (de) | Substituierte thiazolidinedione derivate, ihre herstellung und pharmazeutische zusammensetzungen, die sie enthalten | |
HUP9900154A2 (hu) | Trovafloxacin-mezilát tabletta | |
ATE287264T1 (de) | Oral anzuwendende buprenorphinhaltige arzneimittel | |
DE602004005564D1 (de) | Pharmazeutische Zusammensetzung für Thrombinpeptidderivaten | |
PL346764A1 (en) | New oral formulation for 5-ht4 | |
ITTO960483A0 (it) | Formulazione di polivinile cloruro plastificato per la realizzazione di componenti in materiale biocompatibile, in particolare di linee ematiche. | |
EA200702386A1 (ru) | Твердая фармацевтическая композиция для продолжительного высвобождения 1-(2,3,4-триметоксибензил)пиперазина и способ ее получения | |
ATE332140T1 (de) | Pharmazeutische zusammensetzungen, welche steroidische strukturen enthalten, und deren verwendungen | |
DE602004003719D1 (de) | 9-aminopodophyllotoxinderivate, verfahren zu deren herstellung und pharmazeutische zusammensetzungen, die diese derivate enthalten | |
AU2197695A (en) | Dimeric benzimidazole derivatives, their preparation and their use as dopaminergic agents, esp. selective for the dopamine d3 receptor | |
DE69713586D1 (de) | Dosisformen und deren verwendungen | |
DE602004000016D1 (de) | Schnell freisetzende farmazeutische darreichungsform enthaltend polymorphes tibolon |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 4A,5A,6A E 7A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2073 DE 28/09/2010. |